ArticleScientific reports2025
Comparative study of third-generation sequencing-based CASMA-trio and STR linkage analysis for identifying SMN1 2 + 0 carriers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Locked nucleic acid (LNA) based PCR approach for the diagnosis and screening of spinal muscular atrophy.The Indian journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Spinal Muscular Atrophy (SMA, MIM#253300) is an autosomal recessive neuromuscular disorder caused by defects in the Survival Motor Neuron (SMN) gene. The SMN1 gene, recognized as the primary pathogenic gene for SMA, exhibits a high degree of sequence homology with SMN2 gene. Individuals with the SMN1 2 + 0 genotype represent a unique type of SMA carrier, characterized by two SMN1 copies on one chromosome and zero copies on the other. Accurate identification of this type of carrier is crucial for genetic counseling in families. This study included 28 samples from five SMA families, each with an affected patient carrying a homozygous deletion of the SMN1 gene and a parent suspected to be a SMN1 2 + 0 carrier. Comprehensive Analysis of SMA (CASMA), based on third-generation sequencing technology, was used to detect the SMN1 and SMN2 copy numbers in the samples, and SMN1 2 + 0 carriers were identified through SMN1 haplotypes in parent-child trios (CASMA-trio). The results were compared with those obtained using Multiplex Ligation-dependent Probe Amplification (MLPA) combined with Short Tandem Repeat (STR) linkage analysis. The SMN1 and SMN2 copy numbers detected by MLPA and CASMA were concordant across 25 peripheral blood samples, whereas CASMA failed to accurately determine the copy numbers in the remaining 3 amniotic fluid samples. CASMA-trio identified 5 members from 4 families as SMN1 2 + 0 carriers, which were consistent with the results from STR linkage analysis. However, the two methods yielded inconsistent results for the proband's father in one family. These findings suggest that CASMA has the potential to detect SMN1 and SMN2 copy numbers. Compared to STR linkage analysis, CASMA-trio only requires a parent-child trio to analyze SMN1 2 + 0 carriers, demonstrating a broader application prospect. Implementing CASMA-trio can facilitate comprehensive screening for SMA carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.